keyword
MENU ▼
Read by QxMD icon Read
search

hbv vaccine

keyword
https://www.readbyqxmd.com/read/28340322/immunogenicity-and-safety-of-primary-and-booster-vaccination-with-2-investigational-formulations-of-diphtheria-tetanus-and-haemophilus-influenzae-type-b-antigens-in-a-hexavalent-dtpa-hbv-ipv-hib-combination-vaccine-in-comparison-with-the-licensed-infanrix-hexa
#1
Timo Vesikari, Luis Rivera, Tiina Korhonen, Anitta Ahonen, Brigitte Cheuvart, Marjan Hezareh, Winnie Janssens, Narcisa Mesaros
Safety and immunogenicity of 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens of the combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Hib vaccine (DTPa-HBV-IPV/Hib) were evaluated in a Primary (NCT01248884) and a Booster vaccination (NCT01453998) study. In the Primary study, 721 healthy infants (randomized 1:1:1) received 3 doses of DTPa-HBV-IPV/Hib formulation A (DATAPa-HBV-IPV/Hib), or B (DBTBPa-HBV-IPV/Hib) or the licensed DTPa-HBV-IPV/Hib vaccine (Infanrix hexa, GSK; control group) at 2, 3, 4 months of age...
March 24, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28338458/hepatitis-b-in-solid-organ-transplant-procedures-other-than-liver
#2
Dina Halegoua-De Marzio, Jonathan M Fenkel, Cataldo Doria
Transplant is often the best treatment available for patients with end-stage organ failure. Hepatitis B virus infection in transplant procedures other than liver is a major concern because it can be a significant cause of morbidity and mortality after transplant. Due to the increased risk of hepatic complications, such as fibrosing cholestatic hepatitis or histologic deterioration after transplant, systematic use of nucleoside or nucleotide analogues shortly before or at the time of transplant is recommended (tenofovir or entecavir are preferable to lamivudine) in all patients, whatever the baseline histologic evaluation...
April 2017: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/28335554/complete-and-incomplete-hepatitis-b-virus-particles-formation-function-and-application
#3
REVIEW
Jianming Hu, Kuancheng Liu
Hepatitis B virus (HBV) is a para-retrovirus or retroid virus that contains a double-stranded DNA genome and replicates this DNA via reverse transcription of a RNA pregenome. Viral reverse transcription takes place within a capsid upon packaging of the RNA and the viral reverse transcriptase. A major characteristic of HBV replication is the selection of capsids containing the double-stranded DNA, but not those containing the RNA or the single-stranded DNA replication intermediate, for envelopment during virion secretion...
March 21, 2017: Viruses
https://www.readbyqxmd.com/read/28333957/immune-response-of-rats-vaccinated-orally-with-various-plant-expressed-recombinant-cysteine-proteinase-constructs-when-challenged-with-fasciola-hepatica-metacercariae
#4
Malgorzata Kesik-Brodacka, Agnieszka Lipiec, Monika Kozak Ljunggren, Luiza Jedlina, Katarzyna Miedzinska, Magdalena Mikolajczak, Andrzej Plucienniczak, Andrzej B Legocki, Halina Wedrychowicz
BACKGROUND: Cysteine proteinases of Fasciola hepatica are important candidates for vaccine antigens because of their role in fluke biology and host-parasite relationships. In our previous experiments, we found that a recombinant cysteine proteinase cloned from adult F. hepatica (CPFhW) can protect rats against liver fluke infections when it is administered intramuscularly or intranasally in the form of cDNA. We also observed considerable protection upon challenge following mucosal vaccination with inclusion bodies containing recombinant CPFhW produced in Escherichia coli...
March 23, 2017: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/28333769/the-incidence-of-low-seroimmunity-to-hepatitis-b-virus-in-children-with-inflammatory-bowel-disease
#5
Abhishek Watts, William E Bennett, Jean P Molleston, Sandeep K Gupta, Joseph M Croffie, Shamaila Waseem, Brian A McFerron, Steven J Steiner, Sanjay Kumar, Charles P Vanderpool, Emily C Hon, Molly A Bozic, Girish C Subbarao, Marian D Pfefferkorn
OBJECTIVES: Patients with inflammatory bowel disease (IBD) often receive immunosuppressive therapy which may make them vulnerable to infections such as hepatitis B. We hypothesized that hepatitis B virus (HBV) titers are low in the vaccinated pediatric IBD population. The aims of our study were to identify the incidence of lower titers of hepatitis B surface antibody (HBsAb) and determine which patient factors may be associated with lower HBsAb titers. METHODS: Patients with diagnosis of IBD, ages 5-18 years, were prospectively enrolled...
March 22, 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/28332072/are-the-autoimmune-inflammatory-syndrome-induced-by-adjuvants-asia-and-the-undifferentiated-connective-tissue-disease-uctd-related-to-each-other-a-case-control-study-of-environmental-exposures
#6
F Scanzi, L Andreoli, M Martinelli, M Taraborelli, I Cavazzana, N Carabellese, R Ottaviani, F Allegri, F Franceschini, N Agmon-Levin, Y Shoenfeld, Angela Tincani
The autoimmune/inflammatory syndrome induced by adjuvants (ASIA) is an entity that includes different autoimmune conditions observed after exposure to an adjuvant. Patients with undifferentiated connective tissue disease (UCTD) present many signs and symptoms of ASIA, alluding to the idea that an exposure to adjuvants can be a trigger also for UCTD. The aim of this case-control study was to investigate exposure to adjuvants prior to disease onset in patients affected by UCTD. Ninety-two UCTD patients and 92 age- and sex-matched controls with no malignancy, chronic infections, autoimmune disease nor family history of autoimmune diseases were investigated for exposure to adjuvants...
March 22, 2017: Immunologic Research
https://www.readbyqxmd.com/read/28329932/-an-investigation-on-immunological-effect-of-hepatitis-b-vaccine-amongst-adult-population-in-high-labor-export-rural-regions-under-4-different-strategies
#7
X Y Zheng, Z H Ji, Z W Guo, Y W Liu, Z J Shao, Y P Yan
Objective: To grope for an ideal immune strategy in grown-ups via comparison of immunological effects under 4 different vaccination schemes. Methods: Study population was selected by stratified random cluster sampling. A total of 4 different vaccination proposals, including Strategy A (3 doses, 10 μg, administrated repeatedly into the unilateral deltoid muscle at 0-1-6 months), Strategy B (2 doses, 20 μg, administrated into the bilateral deltoid muscles simultaneously), Strategy C (3 doses, 10 μg, administrated repeatedly into the unilateral deltoid muscle at 0-1-2 months) and Strategy D (2 doses, 10 μg, administrated to the bilateral deltoid muscles at the same time), were conducted in Liangzhou, Minqin Gulang, and the Tianzhu Tibetan Autonomic county respectively, in Wuwei city, Gansu province...
March 10, 2017: Zhonghua Liu Xing Bing Xue za Zhi, Zhonghua Liuxingbingxue Zazhi
https://www.readbyqxmd.com/read/28328809/infectious-diseases-prevalence-vaccination-coverage-and-diagnostic-challenges-in-a-population-of-internationally-adopted-children-referred-to-a-tertiary-care-children-s-hospital-from-2009-to-2015
#8
Sara Sollai, Francesca Ghetti, Leila Bianchi, Maurizio de Martino, Luisa Galli, Elena Chiappini
Infectious diseases are common in internationally adopted children (IAC).With the objective to evaluate infectious diseases prevalence in a large cohort of IAC and to explore possible risk factors for tuberculosis (TB) and parasitic infections, clinical and laboratory data at first screening visit of all IAC (<18 years) consecutively referred to our Center in 2009 to 2015 were collected and analyzed.In total, 1612 children (median age: 5.40 years; interquartile range: 3.00-7.90) were enrolled, 123/1612 (7...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28322457/declining-antibody-levels-after-hepatitis-b-vaccination-in-down-syndrome-a-need-for-booster-vaccination
#9
N B Eijsvoogel, M I Hollegien, L A Bok, A Derksen-Lubsen, F Dikken, A C A P Leenders, A Pijning, E Post, M Wojciechowski, M Hilbink, E de Vries
We determined the anti-HBs titer in 227 children of all ages with Down syndrome (DS). Only 48.1% (95% CI: 35.1-61.3) of the DS children aged 7-10 years and 31.9% (95% CI: 22.1-43.6) of the DS children aged >10 years had a protective anti-HBs titer (≥10 IU/l). The geometric mean anti-HBs titer was significantly lower in the DS children; this suggests booster vaccination for HBV may be needed. This article is protected by copyright. All rights reserved.
March 21, 2017: Journal of Medical Virology
https://www.readbyqxmd.com/read/28322417/reduction-of-acute-hepatitis-b-through-vaccina-tion-of-adolescents-with-no-decrease-in-chronic-hepatitis-b-due-to-immigration-in-a-low-ende-micity-country
#10
Jean-Luc Richard, Christian Schaetti, Sabine Basler, Virginie Masserey Spicher
With a hepatitis B prevalence of 0.3%, Switzerland is a country with low endemicity. Unlike most other countries, Switzerland's recommendation for vaccination against hepatitis B has since 1998 focused on adolescents aged 11 to 15 years rather than on infants, in addition to risk groups since 1982. This paper describes the evolution of the incidence of acute hepatitis B virus (HBV) infection and newly reported chronic cases in Switzerland, as well as their epidemiological features, in order to discuss the implications for the control of hepatitis B through vaccination...
March 21, 2017: Swiss Medical Weekly
https://www.readbyqxmd.com/read/28321220/adjusted-particle-size-eliminates-the-need-of-linkage-of-antigen-and-adjuvants-for-appropriated-t-cell-responses-in-virus-like-particle-based-vaccines
#11
Ariane C Gomes, Anna Flace, Philippe Saudan, Franziska Zabel, Gustavo Cabral-Miranda, Aadil El Turabi, Vania Manolova, Martin F Bachmann
Since the discovery of the first virus-like particle (VLP) derived from hepatitis B virus in 1980 (1), the field has expanded substantially. Besides successful use of VLPs as safe autologous virus-targeting vaccines, the powerful immunogenicity of VLPs has been also harnessed to generate immune response against heterologous and even self-antigens (2-4). Linking adjuvants to VLPs displaying heterologous antigen ensures simultaneous delivery of all vaccine components to the same antigen-presenting cells. As a consequence, antigen-presenting cells, such as dendritic cells, will process and present the antigen displayed on VLPs while receiving costimulatory signals by the VLP-incorporated adjuvant...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28302512/seroepidemiology-of-hepatitis-a-hepatitis-b-and-varicella-virus-in-people-living-with-hiv-in-ireland
#12
Corinna Sadlier, Anna O'Rourke, Alison Carr, Colm Bergin
Epidemiological studies investigating seroprevalence of vaccine preventable infections at both individual and population level are important in guiding screening and vaccination practices. Data on seroprevalence of common vaccine preventable infections in HIV-infected individuals is lacking. We carried out a retrospective cohort study to investigate serological immunity and factors associated with immunity to hepatitis A virus (HAV), hepatitis B virus (HBV) and varicalla virus (VZV) in a cohort of HIV-infected individuals attending a large ambulatory HIV specialist centre in Ireland...
March 13, 2017: Journal of Infection and Public Health
https://www.readbyqxmd.com/read/28302496/community-acquired-pneumococcal-pneumonia-in-virologically-suppressed-hiv-infected-adult-patients-a-matched-case-control-study
#13
Catia Cillóniz, Antoni Torres, Christian Manzardo, Albert Gabarrús, Juan Ambrosioni, Adriana Salazar, Felipe García, Adrián Ceccato, Josep Mensa, Jorge Puig de la Bella Casa, Asunción Moreno, Jose M Miró
BACKGROUND: The study aimed to investigate whether the clinical presentations and outcomes (length-of-stay (LOS), intensive care unit (ICU) admission and 30-day mortality) of pneumococcal pneumonia in virologically suppressed HIV-infected patients on ART with a CD4+ T cell count >350 cells/mm(3) are comparable to those seen in non-HIV-infected patients, using a case-control design. METHODS: A case-control study was carried out in Hospital Clinic, Barcelona, Spain (2001-2016)...
March 13, 2017: Chest
https://www.readbyqxmd.com/read/28301738/active-immunization-against-transforming-growth-factor-beta1-prevents-hepatic-fibrosis-in-a-rat-model-of-liver-disease
#14
Hong Ji, Gerald Y Minuk, Zhikang Peng, Yongping Chen, Chenwei Pan, Yuewen Gong
Transforming growth factor-beta1 (TGF-β1) plays an important role in hepatic fibrogenesis. To document the effects of active immunization against TGF-β1 on hepatic fibrosis in an animal model of chronic liver disease. BALB/c mice were immunized against three different peptides of TGF-β1 ligated into hepatitis B virus core protein (HBVc). Titers of TGF-β1 antibodies were documented by enzyme linked immunoassays and antibody activity by cell membrane receptor binding and proliferation assays. The most immunogenic recombinant HBVc+TGF-β1 peptide (HBVc+C) then served as a vaccine in Sprague-Dawley rats with dimethylnitrosamine-induced chronic liver disease...
March 16, 2017: Canadian Journal of Physiology and Pharmacology
https://www.readbyqxmd.com/read/28299162/sero-prevalence-of-hepatitis-b-surface-antigen-amongst-pregnant-women-attending-an-antenatal-clinic-volta-region-ghana
#15
Arnold Luuse, Sylvester Dassah, Sylvester Lokpo, Louise Ameke, Mark Noagbe, Peter Adatara, Oheneba Hagan, Fred Binka
Hepatitis B virus (HBV) infection remains a global challenge, although there is currently a safe and effective vaccine available. HBV prevalence in Ghana is not well documented, but vary regionally from 4.8% to 12.3% in the general population, 10.8% to 12.7% in blood donors and about 10.6% in pregnant women. This puts Ghana among the high endemic countries in Africa. The study objective was to determine the sero-prevalence of HBs antigen (Ag) and HBeAg among pregnant women in the Ho municipality. Two hundred and eigh participants (pregnant women), attending Ho Municipal antenatal clinic were enrolled into the study...
December 31, 2016: Journal of Public Health in Africa
https://www.readbyqxmd.com/read/28299157/low-coverage-of-hepatitis-b-vaccine-and-determinants-among-health-professionals-working-in-amhara-regional-state-hospitals-ethiopia
#16
Berhanu Elfu Feleke
More than two billion people have been infected with hepatitis B virus (HBV), 360 million have chronic infection and 600,000 die each year from HBV-related liver disease or hepatocellular carcinoma. Each year more than 66,000 health professionals are infected by hepatitis b virus and vaccination against hepatitis B saves the life's of these health professionals. The aim of this study was to determine the prevalence and associated factors of hepatitis B vaccine coverage in a resource limited settings. A cross sectional study design was conducted...
December 31, 2016: Journal of Public Health in Africa
https://www.readbyqxmd.com/read/28295453/low-hepatitis-b-virus-specific-t-cell-response-in-males-correlates-with-high-regulatory-t-cell-numbers-in-murine-models
#17
Anna D Kosinska, Leila Pishraft-Sabet, Weimin Wu, Zhong Fang, Marzena Lenart, Jieliang Chen, Kirsten K Dietze, Cong Wang, Thekla Kemper, Yong Lin, Shiou-Hwei Yeh, Jia Liu, Ulf Dittmer, Zhenghong Yuan, Michael Roggendorf, Mengji Lu
Hepatitis B virus (HBV) infection shows significant gender-related differences in pathogenesis, disease progression, and development of hepatocellular carcinoma. The gender-associated differences in HBV replication and viral protein levels may be associated with distinct HBV-specific immune responses in the host. In the present study, we examined the impact of gender on HBV-specific immune responses in two different mouse models representing transient and persistent hepadnaviral infection; hydrodynamic injection (HI) with the HBV genome mimicked acute HBV infection, whereas the efficacy of therapeutic vaccination was studied in the woodchuck hepatitis virus (WHV) transgenic (Tg) mouse model...
March 13, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28292309/elimination-of-hepatitis-b-is-it-a-mission-possible
#18
REVIEW
Tai-Chung Tseng, Jia-Horng Kao
Chronic hepatitis B virus (HBV) infection is a global public health issue. Although the disease cannot be cured effectively, disease management has been improved over the past decade. The introduction of potent nucleos(t)ide analogues (NAs) to suppress viral replication represented a giant leap in the control of this disease. It has been shown that tenofovir treatment, a potent NA, complements current immunoprophylaxis to diminish mother-to-infant transmission in pregnant women with a high viral load. For patients with chronic HBV infection, quantitative hepatitis B surface antigen is a useful tool to define inactive carriers and to guide antiviral therapy...
March 15, 2017: BMC Medicine
https://www.readbyqxmd.com/read/28285330/hepatitis-b-vaccination-status-in-an-at-risk-adult-population-long-term-immunity-but-insufficient-coverage
#19
S Hustache, L Moyroud, L Goirand, O Epaulard
In France, hepatitis B (HB) vaccine has been offered to all infants since 1994, and was proposed to all children aged 11 years from 1994 to 1998. Nevertheless, HB vaccine hesitancy may result in low vaccination coverage in present-day at-risk adults. We aimed to determine HB vaccination coverage in adults attending a free testing center for sexually transmitted infections (STI). As part of routine care, three classes of data were anonymously collected from attendees over a 3-month period: results of HB serologic tests; date and number of past anti-hepatitis B virus (HBV) immunization(s) (if any) according to health records; and the risk of STI and blood-transmitted infections (BTI)...
March 11, 2017: European Journal of Clinical Microbiology & Infectious Diseases
https://www.readbyqxmd.com/read/28281907/persistence-of-antibodies-20%C3%A2-y-after-vaccination-with-a-combined-hepatitis-a-and-b-vaccine
#20
Pierre Van Damme, Geert Leroux-Roels, P Suryakiran, Nicolas Folschweiller, Olivier Van Der Meeren
Vaccination is the most effective and well-tolerated method of conferring long-term protection against hepatitis A and B viruses (HAV; HBV). Long-term studies are required to characterize the duration of protection and need for boosters. Following primary immunization of 150 and 157 healthy adults with 3-doses of combined hepatitis A/hepatitis B vaccine (HAB; Twinrix™, GSK Vaccines, Belgium) at 0-1-6 months in 2 separate studies, we measured vaccine-induced antibody persistence against HAV and HBV annually for 20 y (Study A: NCT01000324; Study B: NCT01037114)...
March 10, 2017: Human Vaccines & Immunotherapeutics
keyword
keyword
96175
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"